Table 1– Characteristics of all patients according to predominant subtype
All patientsIntermediate group (lepidic and acinar)High group (papillary, micropapillary and solid)p-value
Patients313134 (42.8)123 (39.3)
Age
 <60 years167 (53.4)74 (55.2)63 (51.2)0.816
 >60 years146 (46.6)60 (44.8)60 (48.8)
Sex
 Female187 (59.7)75 (56.0)77 (62.6)0.500
 Male126 (40.3)59 (44.0)46 (37.4)
ECOG
 0–1233 (74.6)99 (73.9)90 (73.6)0.751
 2–480 (25.4)35 (26.1)33 (26.4)
Tumour stage
 III63 (19.8)20 (14.9)33 (26.4)0.065
 IV250 (80.1)114 (85.1)90 (73.6)
Smoking status
 Negative155 (49.5)63 (47.0)67 (54.5)0.354
 Positive158 (50.5)71 (53.0)56 (45.5)
Wood smoke exposure
 Negative179 (57.1)74 (55.2)73 (59.0)0.829
 Positive134 (42.9)60 (44.8)50 (41.0.)
Distant metastasis
 Contralateral lung129 (41.3)55 (41.4)57 (46.3)0.132
 Bones87 (27.9)40 (30.1)30 (24.4)0.539
 CNS87 (27.9)37 (27.8)33 (26.8)0.888
 Liver32 (10.3)10 (7.5)13 (10.6)0.207
 Lymph62 (19.9)23 (17.3)33 (26.8)0.027
 Adrenal glands13 (4.2)5 (3.8)6(4.9)0.878
 Pleural effusion104 (33.3)46 (34.6)37 (30.1)0.572
Signs and symptoms
 Dyspnoea158 (50.5)66 (49.3)64 (52.0)0.353
 Cough208 (66.5)82 (61.2)83 (67.5)0.111
 Weight loss139 (44.4)61 (45.5)55 (44.7)0.850
 Haemoptysis43 (13.7)17 (12.7)15 (12.2)0.364
 Thoracic pain129 (41.2)44 (32.8)60 (48.8)0.029
  • Data are presented as n or n (%), unless otherwise stated. ECOG: Eastern Cooperative Oncology Group; CNS: central nervous system.